BioPharmSignal logoBioPharmSignal

Biotech News

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

Corcept (CORT)CorceptEarnings

Revenue of $164.9 million, compared to $157.2 million in first quarter 2025 Increase in 2026 revenue guidance to $950 – $1,050 million Net loss of $31.8 million, compared to net income of $20.5 million in first quarter 2025 Cash and investments of $515.4 million at March 31, 2026 Lifyorli ™

Open original release

Related news

CORTCorcept2026-04-23 20:05 EST

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

CORTCorcept2026-02-24 21:05 EST

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

VKTXViking Therapeutics2026-04-29 20:05 EST

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

VKTXViking Therapeutics2026-04-22 20:35 EST

Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

CRNXCrinetics Pharmaceuticals2026-05-07 20:05 EST

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

NBIXNeurocrine Biosciences2026-05-05 20:01 EST

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

NBIXNeurocrine Biosciences2026-04-14 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results

CRNXCrinetics Pharmaceuticals2026-02-26 21:05 EST

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

AMPHAmphastar Pharmaceuticals, Inc.2021-03-15 20:05 EST

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020

AMPHAmphastar Pharmaceuticals, Inc.2021-05-06 20:05 EST

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021

View all latest news

Corcept

Corcept Therapeutics is a biotechnology company focused on cortisol modulation and endocrine disease, with a commercial franchise in Cushing’s syndrome and additional pipeline opportunities. Its business combines specialty commercialization with clinical development.

Recent company news

CORTCorcept2026-05-29 20:33 EST

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

CORTCorcept2026-05-27 12:00 EST

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

CORTCorcept2026-04-30 20:05 EST

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

CORTCorcept2026-04-30 20:05 EST

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

CORTCorcept2026-04-23 20:05 EST

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Stock data

Close
91.12 USD
Market cap
7.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States